Biogen Ends Post-Marketing Study of Aduhelm Due to Limited National Coverage Policy

Biogen has terminated a postmarket study of Aduhelm (aducanumab) in patients with Alzheimer’s disease after enrolling just 29 participants.

The FDA granted the antibody accelerated approval in June 2021, but Medicare decided to restrict coverage of the controversial drug in April.

Study investigators said it is “expected there will be limited [Aduhelm] prescription and usage in routine clinical practice making the study not feasible for enrollment.”